TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32213454
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral psychotherapy (individual and group therapy), mean duration: 64.5 days
Study: 34706654
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy and conventional physical therapy
Study: 33485813
Drug: Office Visits
Normalized name: Office First Aid Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office Visits (OVs) where patients brought their medications into the office for review
Study: 34384000
Drug: Dutasteride-Tamsulosin 0.5
Normalized name: dutasteride-tamsulosin 0.5 mg-0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride-Tamsulosin 0.5 mg/0.4 mg capsule formulation (Dakart®)
Study: 34384000
Drug: Combodart® (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combodart® (reference drug)
Study: 34710658
Drug: DPCP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPCP with multi‐concentration patch test
Study: 34710658
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol for immunotherapy
Study: 35279970
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25% ropivacaine with 0.5 μg/kg (1 mL) dexmedetomidine (Group B)
Study: 35279970
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25% ropivacaine with 1 mL of normal saline (Group A)
Study: 32485893
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day biolactis powder (BLP)
Study: 33352723
Drug: Olaparib (PARPi)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (PARPi) + ATR inhibitor AZD6738
Study: 33352723
Drug: Olaparib (PARPi)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (PARPi) + CHK1 inhibitor MK8776
Study: 33352723
Drug: Olaparib (PARPi)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (PARPi) + ATR inhibitor AZD6738 + CHK1 inhibitor MK8776
Study: 36052331
Drug: 3-month cycle
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month cycle of weekly virtual museum tours of the Montreal Museum of Fine Arts (MMFA)
Study: 35997601
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy and education
Study: 33193807
Drug: Convolutional Neural
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Convolutional Neural Network (CNN) with cheat sheet and data augmentation
Study: 33984876
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of lavender aroma
Study: 33984876
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of spring orange aroma
Study: 33638954
Drug: EMDR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR therapy (4 sessions, 60 minutes each) plus standard treatment
Study: 32847923
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (10 mg)
Study: 32847923
Drug: Insulin/glucose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin/glucose intravenous infusion (10 units of short-acting insulin in an intravenous bolus with 500 mL of 10% glucose)
Study: 32847923
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nebulised salbutamol and insulin/glucose intravenous infusion (10 units of short-acting insulin in an intravenous bolus with 500 mL of 10% glucose combined with 10 mg of nebulised salbutamol)
Study: 33836990
Drug: Intravitreal conbercept
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal conbercept (IVC) 0.25 mg/0.025 mL
Study: 33045627
Drug: Percutaneous pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous pulsed radiofrequency treatment of the dorsal root ganglia
Study: 33045627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no radiofrequency treatment)
Study: 32827209
Drug: Bupivacaine combined
Normalized name: bupivacaine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine combined with ketorolac 15 mg/side for TAP block (TK group)
Study: 32827209
Drug: Bupivacaine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine for TAP block and 30 mg postoperative intravenous ketorolac (T group)
Study: 32827209
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg postoperative intravenous ketorolac alone (C group)
Study: 32164142
Drug: Post-marketing vaccines
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-marketing vaccines (specific types mentioned: influenza, rotavirus, cholera, pneumonia, EV71)
Study: 38198456
Drug: MDMA-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-assisted therapy
Study: 32223100
Drug: Sildenafil regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil regular (50 mg qd)
Study: 32223100
Drug: Sildenafil on-demand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil on-demand (100 mg 30 minutes before intercourse)
Study: 32223100
Drug: Tadalafil regular
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil regular (10 mg qd)
Study: 34920291
Drug: Gatipotuzumab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatipotuzumab (500 mg followed by 1700 mg 1 week later) every 3 weeks until tumor progression or unacceptable toxicity
Study: 36396522
Drug: Colchicine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1.5 mg/day
Study: 36240638
Drug: Probiotics (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (1 g/kg and 2 g/kg)
Study: 36240638
Drug: Diet acidifier
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet acidifier (2 g/kg and 3 g/kg)
Study: 36240638
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of probiotics and acidifier
Study: 34156097
Drug: Topical epinephrine
Normalized name: epinephrine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical epinephrine 1:1,000
Study: 34156097
Drug: Topical epinephrine
Normalized name: epinephrine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical epinephrine 1:10,000
Study: 35593928
Drug: Collagen membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen membrane group (CM) - collagen membrane coverage after rotary instrument preparation
Study: 33093297
Drug: Informational video
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informational video for patients regarding antibiotics in diverticulitis
Study: 33093297
Drug: Evidence summaries
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence summaries for physicians regarding antibiotics in diverticulitis
Study: 33093297
Drug: Non-antibiotic strategy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antibiotic strategy
Study: 35126605
Drug: Yushen Tongluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yushen Tongluo Granule (YSTLG) combined with Clomiphene Citrate (CC)
Study: 33184166
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injectate (3 x 10 mL aliquots)
Study: 33184166
Drug: Sham injectates
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injectates (3 x 10 mL)
Study: 35121091
Drug: Nefopam (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (80 mg continuous intravenous infusion for 24 hours)
Study: 35598597
Drug: Tanshinone IIA
Normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanshinone IIA (TSA) at concentrations of 1 μg/mL, 10 μg/mL, 100 μg/mL, and 1 mg/mL plus 5 U/mL of thrombin
Study: 35598597
Drug: 5 U/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 U/mL of thrombin
Study: 36354237
Drug: PureRegen Gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PureRegen Gel (PRG)
Study: 32708973
Drug: Iron-rich diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-rich diet (iron intake >20 mg/day)
Study: 32708973
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (FS) supplementation (105 mg/day)
Study: 34518652
Drug: Enzalutamide plus
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide plus androgen deprivation therapy (ADT)
Study: 33433597
Drug: Salt nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt nicotine formulation (benzoic acid added)
Study: 32357362
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol maleate (TTM) 0.5% solution for 12 months
Study: 32357362
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol maleate (TTM) 0.5% solution
Study: 32267471
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg, subcutaneously at weeks 0 and 4
Study: 36162893
Drug: 1-visit root
Normalized name: Mugwort root
DrugBank: Artemisia vulgaris root (DB14170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-visit root canal treatment with 2% chlorhexidine (CHX) as final irrigant
Study: 36162893
Drug: 2-visit root
Normalized name: Mugwort root
DrugBank: Artemisia vulgaris root (DB14170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-visit root canal treatment with calcium hydroxide (CH) dressings
Study: 33028480
Drug: MAP +
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAP + Treatment as Usual (TAU)
Study: 33907936
Drug: One-implant group
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-implant group (n = 23)
Study: 33907936
Drug: Two-implant group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant group (n = 24)
Study: 32211907
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg (0.05 mL)
Study: 32796329
Drug: Buried Intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buried Intradermal Suture (BIS)
Study: 35488808
Drug: Art Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art Therapy Group (ATG)
Study: 35488808
Drug: Art Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art Therapy Group (ATG) with initial severe mental fatigue (MFF)
Study: 35488808
Drug: Art Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art Therapy Group (ATG) with initial poor motivation
Study: 35488808
Drug: Art Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art Therapy Group (ATG) with chemotherapy
Study: 35488808
Drug: Standard Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Group (SG) with chemotherapy
Study: 37592290
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy
Study: 36442482
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic target <40th percentile)
Study: 33834643
Drug: Desmopressin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin plus anticholinergic (propiverine 5 mg)
Study: 33834643
Drug: Desmopressin (monotherapy)
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (monotherapy)
Study: 35870327
Drug: Parent-based treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-based treatment
Study: 34301613
Drug: brolucizumab 6
Normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
Approvals — FDA: no, EMA: no, PMDA: no
Description: brolucizumab 6 mg
Study: 33187542
Drug: Smartphone-assisted problem-solving
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-assisted problem-solving therapy
Study: 33059084
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation treatment (Control)
Study: 34472929
Drug: Mindfulness Meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness Meditation (MM), Cognitive Therapy (CT), Mindfulness-Based Cognitive Therapy (MBCT)
Study: 34237764
Drug: Usual discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual discharge pain medication instructions
Study: 35012708
Drug: ESS plus
Normalized name: Stress Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESS plus medical therapy
Study: 35065931
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of PM2.5 exposure (≥ 129.9 and ≤ 2100 μg/m3)
Study: 33211109
Drug: Long-term current
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term current low-dose aspirin use
Study: 33211109
Drug: Episodic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Episodic low-dose aspirin use
Study: 33211109
Drug: Long-term current
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term current low-dose aspirin use (subcohort aged 40-59 years)
Study: 33211109
Drug: Episodic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Episodic low-dose aspirin use (subcohort aged 40-59 years)
Study: 33211109
Drug: No low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No low-dose aspirin use (control group)
Study: 34656303
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg) and elemental zinc (30 mg) daily for 6 months
Study: 32467559
Drug: Immediate-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tacrolimus (0.2 mg/kg/day)
Study: 32467559
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus (0.2 mg/kg/day)
Study: 32467559
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus (0.3 mg/kg/day)
Study: 32467559
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus (0.2 mg/kg/day) plus basiliximab
Study: 35675611
Drug: Same-day cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day cervical preparation with osmotic dilators plus buccal misoprostol
Study: 33431358
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with combination cisplatin (50 mg/m2) plus doxorubicin (15 mg/m2)
Study: 33431358
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with intense single-agent cisplatin (100 mg/m2)
Study: 35862782
Drug: Simvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (80 mg intragastric administration)
Study: 35862782
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no simvastatin treatment)
Study: 33674231
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy (Med)
Study: 33031018
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BR) - 70 mL (∼5 mmol nitrate)
Study: 33031018
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) - 70 mL (∼0.003 mmol nitrate)
Study: 35500015
Drug: READY (Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: READY (Acceptance and Commitment Therapy-based group resilience-training program)
Study: 35307538
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy with medication management as needed
Study: 35307538
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care psychoeducation with medication management as needed
Study: 35307538
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Family-focused therapy and Enhanced care psychoeducation)
Study: 34129239
Drug: Antithrombotic therapies
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapies (ATT)
Study: 34129239
Drug: Monotherapy (Low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (Low-dose aspirin)
Study: 34129239
Drug: DAPT (Aspirin/Clopidogrel)
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (Aspirin/Clopidogrel)
Study: 35448942
Drug: IV HBB
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV HBB 20 mg in 1 ml (Hyoscine group)
Study: 32685258
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid (10 mg/kg)
Study: 33827781
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy in earlier trials
Study: 35422208
Drug: Regional Anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional Anesthesia (RA) with Dexmedetomidine (DEX: 1 μg/kg infused over 10 min followed by 0.5 μg/kg/h)
Study: 35422208
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Anesthesia (GA) with Dexmedetomidine (DEX: 0.1 μg/kg/min over 10 min followed by 0.4‐0.7 μg/kg/h)
Study: 32594135
Drug: prednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone (10 mg daily) plus 5α-reductase inhibitor (finasteride 5 mg daily or dutasteride 0.5 mg daily)
Study: 32594135
Drug: prednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone (10 mg daily)
Study: 36120087
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol 3350 17g once daily for 24 weeks
Study: 35177180
Drug: Budesonide combined
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide combined with pulmonary surfactant (PS) at a dose of 0.25 mg/kg for intratracheal instillation with PS application.
Study: 35177180
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with pulmonary surfactant (PS) alone at an initial dose of 200 mg/kg, followed by 100 mg/kg according to the condition.
Study: 32151211
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of intravenous zoledronate
Study: 35608106
Drug: Oral infigratinib
Normalized name: infigratinib
DrugBank: Infigratinib (DB11886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral infigratinib 125 mg daily on days 1-21 of a 28-day cycle for up to 52 weeks
Study: 37332625
Drug: Standard literacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard literacy promotion (beginning at 6 months, only weekly text messages on safety)
Study: 33398890
Drug: Mefloquine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (2 doses taken as a split dose with a meal)
Study: 33398890
Drug: Sulfadoxine–pyrimethamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine–pyrimethamine (4 doses)
Study: 35329896
Drug: Exergame intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exergame intervention (20 minutes, twice per week)
Study: 32499254
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus KOMPACT (2 hours 20 minutes of preoperative physiotherapy informed by Acceptance and Commitment Therapy)
Study: 33070288
Drug: Alpelisib 300
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib 300 mg in fasted state
Study: 33070288
Drug: Pivotal clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivotal clinical formulation (PCF) and commercial formulation (CF)
Study: 32857331
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days antibiotics
Study: 32857331
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days antibiotics
Study: 34151493
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine (3 mg/kg/day) for 4 months
Study: 34151493
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone mini pulse (2.5 mg dexamethasone on two consecutive days/week for 4 months)
Study: 32700655
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg oral daily (group RXE)
Study: 34302514
Drug: 8% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% capsaicin treatment